Veeva Systems Cl A saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 65 to 74.
IBD's proprietary rating identifies share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks typically have an RS Rating of above 80 in the early stages of their moves. See if Veeva Systems Cl A can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
While now is not an ideal time to invest, see if the stock is able to establish and enter a buying range in heavy volume.
Veeva Systems Cl A reported 34% earnings growth in its most recent report, while sales growth came in at 15%. The company is expected to report its latest performance numbers on or around Dec. 5.
The company holds the No. 2 rank among its peers in the Computer Software-Medical industry group. Doximity is the top-ranked stock within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
